# OnCo record paper-dll3-sclc-clin-cancer-res-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-dll3-sclc-clin-cancer-res-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-dll3-sclc-clin-cancer-res-2019" ;
  schema:name "Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study"@en ;
  schema:description "Phase 2 or 3 results paper on DLL3 in Small-cell lung cancer, in Clinical Cancer Research (2019), one of the most cited Europe PMC records with DLL3 in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-dll3-sclc-clin-cancer-res-2019/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.ccr-19-1133>, <https://pubmed.ncbi.nlm.nih.gov/31506387/>, <https://europepmc.org/article/MED/31506387> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.ccr-19-1133> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Morgensztern D, Besse B, Greillier L, et al." ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .